Childhood cancer survivors have an increased risk for venous thromboembolism (VTE) that persists across their lifespan, according to results from the multi-institutional Childhood Cancer Survivor Study (CCSS) cohort of more than 24,000 5-year survivors and 5,000 siblings. Read more: https://www.medpagetoday.com/cardiology/venousthrombosis/75232
Childhood cancer survivors are at a much greater risk of developing HPV-related cancer than the general population, yet far less likely to get vaccinated. Read more: http://www.tpr.org/post/childhood-cancer-survivors-greater-risk-developing-hpv-related-cancer
Men who have been treated for childhood cancers are at increased risk for the sexual issues that all aging men face, specifically a 2.6-fold increased risk for developing erectile dysfunction. Read more: http://www.cancernetwork.com/patient-care/rates-erectile-dysfunction-higher-childhood-cancer-survivors
Female childhood cancer survivors who developed breast cancer later in life appeared more than twice as likely to die of any cause than women with breast cancer who never had a childhood malignancy, according to study results. Read more: https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B20da77b3-be87-4b8a-b5d9-e959764c4a53%7D/mortality-risk-after-breast-cancer-greater-among-those-who-survived-childhood-cancers
Adults who had brain cancer as children may have a harder time living independently and having rich professional and personal lives than people who didn’t have these tumors in childhood, a U.S. study suggests. Read more: https://www.reuters.com/article/us-health-brain-cancer-children/adult-survivors-of-childhood-brain-tumors-may-struggle-to-live-independently-idUSKCN1LT38D
Novartis is pleased to announce that following a Priority Review, Health Canada has approved Kymriah™ (tisagenlecleucel/ CTL019) the first chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in Canada.